Deutsche Bank downgrades Biogen-IDEC (Nasdaq: BIIB) from Buy to Hold. Maintaining $55 price target.

Deutsche analyst says, "We are downgrading ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE